Clinical trial GRASPA-TNBC-2018-02
A Randomized Phase 2/3 Study of Eryaspase in Combination with Gemcitabine and Carboplatin Chemotherapy versus Chemotherapy Alone As First-Line Treatment in Patients with Metastatic or Locally Recurrent Triple-Negative Breast Cancer
Cancers | |
---|---|
Organ | Breast |
Trial status | Trial closed |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 2/3 |
Academic trial | Non |
Sponsor | Erytech |
EudraCT Identifier | 2018-002211-10 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03674242 |
Inclusion criteria | Triple negative |
Last update |